Solventum Reports Second Quarter 2026 Financial Results

* Reported sales increased 2.2%; organic sales increased 9.5% * Announces intent to separate its Health Information Systems business segment * Increases full-year 2026 guidance for organic sales growth, adjusted EPS and free cash flow EAGAN, Minn., Aug. 5, 2026 /PRNewswire/ -- Solventum (NYSE: SOLV) today reported financial results for the second quarter ended June 30, 2026.

* Sales of $2.2 billion, increased 2.2% on a reported basis; an increase of 9.5% on an organic basis * GAAP diluted earnings per share of $0.53; adjusted diluted earnings per share of $2.55, a 50.9% increase * Operating cash flow of $227 million; free cash flow of $144 million "The Solventum team delivered another quarter of strong execution with results ahead of our expectations while continuing to advance our transformation," said Bryan Hanson, chief executive officer of Solventum. "We remain on track to achieve our long-term objectives as we build a more focused, dedicated MedTech company, well-positioned to create long-term shareholder value." Second Quarter and First Six Months 2026 Financial Results